Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in EU-27 is a rapidly growing market, driven by various factors such as increasing prevalence of autoimmune diseases, advancements in medical technology, and rising healthcare expenditure.
Customer preferences: Patients suffering from autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease prefer immunosuppressants as they help in controlling the symptoms of the disease and improve the quality of life. Additionally, the use of immunosuppressants in organ transplant surgeries is also driving the demand for these drugs.
Trends in the market: Germany is the largest market for immunosuppressants in the EU-27 region, followed by France and the UK. The market is expected to witness a significant growth in the coming years due to the increasing prevalence of autoimmune diseases. The demand for branded immunosuppressants is high due to the perceived higher efficacy and safety of these drugs. However, the market is witnessing a shift towards generic immunosuppressants due to the high cost of branded drugs and the increasing pressure on healthcare budgets.
Local special circumstances: The EU-27 region has a well-established healthcare system with universal health coverage. This has led to a higher demand for immunosuppressants, as patients have better access to healthcare facilities and can afford expensive treatments. Additionally, the region has a high aging population, which is more susceptible to autoimmune diseases, further driving the demand for immunosuppressants.
Underlying macroeconomic factors: The EU-27 region has a stable economy and a high standard of living, which has led to an increase in healthcare expenditure. Additionally, the region has a strong pharmaceutical industry, which is investing heavily in research and development of new immunosuppressants. However, the region is also facing challenges such as rising healthcare costs and the increasing burden of chronic diseases, which is putting pressure on healthcare budgets. This is leading to a shift towards cost-effective treatments such as generic drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
